Congenica scales genomic medicine push with new deal in China
Cambridge, UK based digital health pioneer, Congenica has taken significant strides towards dominating the potentially huge personalised medicines market in China.
It is customising its global diagnostic decision support platform for the territory after signing a new strategic partner – Digital China Health Technologies Cooperation Limited (DCHealth).
The deal was officially signed in China where Congenica was part of the UK Government’s trade delegation to the World Economic Forum Annual Meeting of the New Champions led by Health Secretary, Matt Hancock.
The alliance will see Congenica develop a version of its Sapientia™ platform designed to enable clinicians and patients in China to benefit from the clinical genomics and personalised medicine revolution.
DCHealth will use its significant commercial depth and experience in the Chinese hospital market to accelerate the commercialisation of this locally-adapted version of Sapientia™.
Congenica’s Sapientia platform and expert support services allow clinicians to interrogate the human genome to identify disease-causing variants.
Congenica aims to revolutionise personalised patient care through accurate diagnoses, curation of evolving knowledge bases, and support in clinical trials and drug development. With the ability to interrogate all disease-causing variants, it has particular capability to support identification of those for rare diseases.
DCHealth has established a nationwide cancer data network connecting 30 specialised cancer hospitals and 174 municipal cancer hospitals across China.
It participated in various national projects including building the National Rare Disease Registry System of China. DCHealth has also years of experience working with hospitals in China to build IT systems that enhance patient care.
Dr David Atkins, CEO of Congenica, said: “China is an important market for Congenica and this new relationship with DCHealth gives us greater insight into what the local market requires to accelerate the broader use of genomic medicine. This comprehensive commercial partnership will give us extensive market insight and access.
“We also recognise the need to automate Sapientia to support wider usage and to help reduce costs to healthcare providers, helping more clinicians provide accurate, rapid and cost-effective diagnoses to patients and their families.”
David Shi, CEO of DCHealth, added: “As the provision of routine clinical genomics services continues to increase in China and other global markets, the analysis and interpretation of genomic data will be one of the most challenging aspects of transforming these data into meaningful, clinically-actionable results.
“Our business partnership reflects Congenica’s proven abilities and track record and underlines our confidence that its clinical genomic diagnostics platform and services will support clinicians with definitive diagnoses and facilitate the delivery of consistently high quality of care.”
Combining its heritage from the Wellcome Trust Sanger Institute with real-world commercial and clinical experience through work with Genomics England’s 100K Genomes Project, in addition to NHS Genomic Medicine Centres and NHS Trusts across the UK, Sapientia helps clinicians quickly identify the genetic variants that cause disease to support clinical decision-making.
It has also played a role in a number of other significant national-scale genomics projects including China’s 100K Wellness Project.